183 related articles for article (PubMed ID: 38127915)
21. Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.
Vranceanu AM; Manglani HR; Choukas NR; Kanaya MR; Lester E; Zale EL; Plotkin SR; Jordan J; Macklin E; Bakhshaie J
JAMA Netw Open; 2023 Jun; 6(6):e2320599. PubMed ID: 37378983
[TBL] [Abstract][Full Text] [Related]
22. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
[TBL] [Abstract][Full Text] [Related]
23. Mind-Body Therapy via Videoconferencing in Patients With Neurofibromatosis: Analyses of 1-Year Follow-up.
Lester EG; Gates MV; Vranceanu AM
Ann Behav Med; 2021 Feb; 55(1):77-81. PubMed ID: 32421171
[TBL] [Abstract][Full Text] [Related]
24. Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis-Practice Resource of the National Society of Genetic Counselors.
Radtke HB; Bergner AL; Goetsch AL; McGowan C; Panzer K; Cannon A
J Genet Couns; 2020 Oct; 29(5):692-714. PubMed ID: 32602153
[TBL] [Abstract][Full Text] [Related]
25. Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
Ahlawat S; Blakeley JO; Langmead S; Belzberg AJ; Fayad LM
Skeletal Radiol; 2020 Feb; 49(2):199-219. PubMed ID: 31396668
[TBL] [Abstract][Full Text] [Related]
26. Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial.
Vranceanu AM; Zale EL; Funes CJ; Macklin EA; McCurley J; Park ER; Jordan JT; Lin A; Plotkin SR
JMIR Res Protoc; 2018 Oct; 7(10):e11008. PubMed ID: 30355560
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
Blakeley JO; Plotkin SR
Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632
[TBL] [Abstract][Full Text] [Related]
28. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
Ahlawat S; Fayad LM; Khan MS; Bredella MA; Harris GJ; Evans DG; Farschtschi S; Jacobs MA; Chhabra A; Salamon JM; Wenzel R; Mautner VF; Dombi E; Cai W; Plotkin SR; Blakeley JO; ;
Neurology; 2016 Aug; 87(7 Suppl 1):S31-9. PubMed ID: 27527647
[TBL] [Abstract][Full Text] [Related]
29. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.
Plotkin SR; Bredella MA; Cai W; Kassarjian A; Harris GJ; Esparza S; Merker VL; Munn LL; Muzikansky A; Askenazi M; Nguyen R; Wenzel R; Mautner VF
PLoS One; 2012; 7(4):e35711. PubMed ID: 22558206
[TBL] [Abstract][Full Text] [Related]
30. First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis.
Talaei-Khoei M; Riklin E; Merker VL; Sheridan MR; Jordan JT; Plotkin SR; Vranceanu AM
J Neurooncol; 2017 Jan; 131(2):413-419. PubMed ID: 27900643
[TBL] [Abstract][Full Text] [Related]
31. Neurofibromatoses: part 1 - diagnosis and differential diagnosis.
Rodrigues LO; Batista PB; Goloni-Bertollo EM; de Souza-Costa D; Eliam L; Eliam M; Cunha KS; Darrigo-Junior LG; Ferraz-Filho JR; Geller M; Gianordoli-Nascimento IF; Madeira LG; Malloy-Diniz LF; Mendes HM; de Miranda DM; Pavarino EC; Baptista-Pereira L; Rezende NA; Rodrigues Lde O; da Silva CM; de Souza JF; de Souza ML; Stangherlin A; Valadares ER; Vidigal PV
Arq Neuropsiquiatr; 2014 Mar; 72(3):241-50. PubMed ID: 24676443
[TBL] [Abstract][Full Text] [Related]
32. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
Lu-Emerson C; Plotkin SR
Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
[TBL] [Abstract][Full Text] [Related]
33. Depression explains the association between pain intensity and pain interference among adults with neurofibromatosis.
Doorley JD; Greenberg J; Bakhshaie J; Fishbein NS; Vranceanu AM
J Neurooncol; 2021 Sep; 154(2):257-263. PubMed ID: 34409538
[TBL] [Abstract][Full Text] [Related]
34. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use.
Bettegowda C; Upadhayaya M; Evans DG; Kim A; Mathios D; Hanemann CO;
Neurology; 2021 Aug; 97(7 Suppl 1):S91-S98. PubMed ID: 34230207
[TBL] [Abstract][Full Text] [Related]
35. A Systematic Review of Recent and Ongoing Clinical Trials in Patients With the Neurofibromatoses.
Acar S; Nieblas-Bedolla E; Armstrong AE; Hirbe AC
Pediatr Neurol; 2022 Sep; 134():1-6. PubMed ID: 35759947
[TBL] [Abstract][Full Text] [Related]
36. [Segmental schwannomatosis in upper-extremity: 5 cases report and literature review].
Wang ZX; Chen SL; Yi CJ; Li C; Rong YB; Tian GL
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Oct; 45(5):698-703. PubMed ID: 24136261
[TBL] [Abstract][Full Text] [Related]
37. Advances in the treatment of neurofibromatosis-associated tumours.
Lin AL; Gutmann DH
Nat Rev Clin Oncol; 2013 Nov; 10(11):616-24. PubMed ID: 23939548
[TBL] [Abstract][Full Text] [Related]
38. Virtual mind-body treatment for adolescents with neurofibromatosis: Study protocol for a single-blind randomized controlled trial.
Reichman M; Riklin E; Macklin E; Vranceanu AM
Contemp Clin Trials; 2020 Aug; 95():106078. PubMed ID: 32634485
[TBL] [Abstract][Full Text] [Related]
39. Neurofibromatosis type 2 (NF 2) or schwannomatosis?--Case report study and diagnostic criteria.
Radek M; Tomasik B; Wojdyn M; Snopkowska-Wiaderna D; Błaszczyk M; Radek A
Neurol Neurochir Pol; 2016; 50(3):219-25. PubMed ID: 27154453
[TBL] [Abstract][Full Text] [Related]
40. Pediatric schwannomatosis, a rare but distinct form of neurofibromatosis.
Thomas AK; Egelhoff JC; Curran JG; Thomas B
Pediatr Radiol; 2016 Mar; 46(3):430-5. PubMed ID: 26546566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
